Zilucoplan

What is Zilucoplan?#

Zilucoplan (marketed as Zilbrysq) is a first-in-class synthetic macrocyclic peptide that inhibits complement component C5, a key mediator of the terminal complement cascade. Developed by Ra Pharmaceuticals (now a wholly owned subsidiary of UCB), zilucoplan was approved for the treatment of generalized myasthenia gravis (gMG) in anti-acetylcholine receptor (AChR) antibody-positive adults in Japan (September 2023), the United States (October 2023), and the European Union (December 2023).

Generalized myasthenia gravis is an autoimmune neuromuscular disorder in which autoantibodies (most commonly against AChR) activate the complement cascade at the neuromuscular junction, leading to destruction of the postsynaptic membrane and impaired neuromuscular transmission. Complement-mediated damage is a central pathogenic mechanism, making C5 inhibition a rational therapeutic strategy.

Zilucoplan is the first self-administered, once-daily subcutaneous C5 complement inhibitor, offering a significant convenience advantage over existing intravenous C5 inhibitors such as eculizumab (biweekly IV infusion) and ravulizumab (every 8 weeks IV infusion).

Mechanism of Action#

Zilucoplan inhibits complement C5 through a dual mechanism of action that distinguishes it from antibody-based C5 inhibitors:

• C5 cleavage inhibition: Zilucoplan binds with high affinity to C5 and prevents its cleavage by the C5 convertase into C5a (a potent anaphylatoxin) and C5b (the initiating component of the membrane attack complex)
• C5b-C6 blockade: By binding to the C5b moiety of C5, zilucoplan sterically hinders the binding of C5b to C6, preventing assembly of the membrane attack complex (MAC) even if residual C5 cleavage occurs
• Complement inhibition: At the approved dose of 0.3 mg/kg daily, zilucoplan achieves approximately 97.5% complement inhibition by the end of the first week of treatment
• Neuromuscular junction protection: By blocking MAC formation at the neuromuscular junction, zilucoplan prevents complement-mediated destruction of the postsynaptic membrane, preserving AChR density and neuromuscular transmission

This dual mechanism provides comprehensive terminal complement pathway blockade, reducing both the inflammatory (C5a-mediated) and cytolytic (MAC-mediated) arms of complement activation.

Clinical Development#

Zilucoplan has been evaluated in a focused clinical program for generalized myasthenia gravis:

• Phase 2 study: Dose-finding study that identified 0.3 mg/kg as the clinically efficacious dose, demonstrating significant improvement in MG-ADL scores
• RAISE (Phase 3): Published in The Lancet Neurology 2023, demonstrated significant MG-ADL improvement vs placebo (P=0.0004) with a favorable safety profile across 174 patients at 75 sites
• RAISE-XT (OLE): Ongoing open-label extension in 200 patients confirming sustained efficacy through 60+ weeks and long-term tolerability
• Regulatory approvals: Japan (September 2023), US FDA (October 2023), EU (December 2023); under review in Australia and Canada

Important Considerations#

Zilucoplan is an FDA-approved prescription medication available only through a restricted program (ZILBRYSQ REMS). Key considerations include:

• Complement inhibition increases the risk of serious meningococcal infections (boxed warning); meningococcal vaccination for serogroups A, C, W, Y, and B is required at least 2 weeks before the first dose
• Life-threatening and fatal meningococcal infections have occurred in patients treated with complement inhibitors, including vaccinated patients
• Available only through the ZILBRYSQ REMS program due to infection risk
• Injection site reactions (primarily bruising) are the most common adverse event
• Approved only for anti-AChR antibody-positive gMG; efficacy in seronegative or MuSK antibody-positive MG has not been established

Key Research Findings#

Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE), published in The Lancet Neurology (Howard JF et al., 2023; PMID: 37059508):

• MG-ADL score improved by -4.39 with zilucoplan vs -2.30 with placebo at 12 weeks (P=0.0004)
• TEAEs occurred in 77% of zilucoplan patients vs 70% placebo; injection-site bruising was the most common (16%)
• No major safety findings; favorable benefit-risk profile in a broad AChR-positive gMG population

Long-term safety and efficacy of zilucoplan (RAISE-XT), published in Therapeutic Advances in Neurological Disorders (Howard JF et al., 2024; PMID: 38638673):

• Sustained MG-ADL improvement maintained through 60 weeks of open-label treatment
• Favorable long-term safety profile in 200 patients with median exposure of 1.2 years

Related Reading#

• Zilucoplan research studies and evidence
• Zilucoplan dosing protocols
• Zilucoplan side effects profile
• Rusfertide research guide